For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- FPMAJ Finalizes Voluntary Plan for Energy-saving this Summer
May 2, 2011
- Acronet, ICON to Collaborate in CRO Business
May 2, 2011
- OTC Ketotifen to be Reclassified as Class 2
May 2, 2011
- FPMAJ Proposes Rotating Production for Some Makers this Summer
May 2, 2011
- “Generally Favorable”Outlook for Dispensing Pharmacies in FY2011: Analyst
May 2, 2011
- What Is on the Mind of Japan's Pharmaceutical Executives?
May 2, 2011
- Quake-hit Plant to Return to Full Operation by Sept.: Chugai
May 2, 2011
- 33 Drugs Approved Including LIXIANA
May 2, 2011
- Bayer Starts Multinational PIII Trial for VEGF Trap-Eye in DME
May 2, 2011
- Production of Pravastatin Drug Substance to Resume in Sept.: Daiichi Sankyo
May 2, 2011
- Eisai's Halaven for Inoperable Breast Cancer
May 2, 2011
- Lixisenatide Reduces HbA1c in Combination with SU or SU + Metformin
May 2, 2011
- No Problem with Radioactive Contamination of Drugs: FPMAJ
May 2, 2011
- Daiichi Sankyo's Edoxaban for VTE Prevention
May 2, 2011
- Toyobo, Kyowa Medex to Comarket GENECUBE
May 2, 2011
- DSP's 200 Pharmacist Employees to Volunteer in Disaster Area
May 2, 2011
- Mochida's Lexapro for Depression
May 2, 2011
- Drugs Provided Free of Charge to Be Reimbursed in Disaster Areas
May 2, 2011
- Astellas Pharma Announces Changes in Leadership
May 2, 2011
- Japan's 1st Transdermal Patch for AD Rivastigmine: Novartis, Ono
May 2, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…